CLEAR

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant (CLEAR)

Patient Information

This trial is evaluating the use of bempedoic acid 180 mg vs. a placebo in overall cholesterol reduction. It works like a statin to reduce cholesterol without the statin side effects of muscle aches and joint pain. This is a world-wide study enrolling 12,700 patients. This is a 3-3½ year study.

Study Contact: cardiovascularresearch@conehealth.com

Study Number

2162

Principal Investigator(s)

Brian Crenshaw, MD

Clinical Trial Categories

• Cholesterol/Diabetes/Hypertension